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A structurally and functionally diverse T-cell 
repertoire is essential for each of the key roles of 
the adaptive immune system: elimination of foreign 
pathogens, provision of immunological memory and the 
maintenance of tolerance to self. T-cells develop in the 
thymus and then migrate to the periphery where they 
undergo activation and functional differentiation following 
contact with cognate antigen via their T-cell receptor 
(TCR). TCR signaling and co-stimulation trigger a cascade 
of intracellular events that culminate in the activation 
of AP-1, NFκB and NFAT proteins, which mediate the 
subsequent transcriptional response. Throughout their 
lifespan T-cells make multiple fate decisions. During 
development and activation, the strength, context and 
timing of the TCR signal is important in determining the 
functional activity of the cell. CD4+ T-helper (Th) cells in 
particular exhibit context-dependent functional plasticity, 
which is apparently regulated by a complex network of 
cytokine signals, many of which are derived from the local 
cell milieu. 
Given the potential plasticity of CD4+ T-cells and 
the growing appreciation for the role of a cell’s local 
environment in its fate and function, it is important to 
understand the ways in which environmental cues integrate 
with TCR signaling. Such signals include molecules that 
activate Gli transcription factors in T-cells. Gli proteins 
are the downstream effectors of canonical Hedgehog (Hh) 
signalling. There is an established negative regulatory role 
for Hh signalling and/or the activation of Gli-dependent 
transcription at the TCR-dependent stages of T-cell 
development in the thymus [1-4]. Hh/Gli-driven signaling 
is also important in the differentiation and function of 
peripheral Th2 cells, which are involved in asthma and 
allergic immune responses [5] and in naïve CD4+ T-cells 
during TCR signaling [1, 2, 6]. Gli transcription factors 
are expressed in wild-type (WT) T-cells [6, 7]. Our 
recent study showed that expression of the transcriptional 
activator form of Gli2 (Gli2A) in CD4+ T-cells decreased 
the ability of T-cells to activate, proliferate and produce 
interleukin-2 (IL-2) in response to TCR stimulation. 
T-cell calcium flux in response to TCR ligation was 
also impaired in Gli2A cells, which also showed lower 
expression of nuclear NFAT2 [6]. Microarray analysis 
of transcriptional responses to Gli2A and Gli2R (the 
repressor form of Gli2) in CD4+ T-cells revealed a wide 
range of differentially expressed transcripts including 
members of the wider morphogen family and other 
genes involved in differentiation and death. Importantly, 
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Figure 1: Proposed immunomodulatory role for Hh/Gli signaling. Schematic diagram suggesting a potential role of Hh/Gli 
signaling in anti-tumour immunity. Certain tumour cells secrete Hh protein ligands, activating Gli-dependent transcription in tumour-
infiltrating T-cells. Gli2A attenuates the intracellular events downstream of TCR signaling including the calcium flux and AP-1/NFκB 
activity. The subsequent transcriptional response to the TCR stimulus is dampened, skewing the T-cell response and potentially aiding 
tumour evasion.
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genes encoding key TCR signalling molecules were 
differentially expressed between WT, Gli2A and/or Gli2R 
CD4+ cells. These included components of the AP-1 
transcriptional complex (Jun, Fos, Fosb) and members of 
the NF-kappa-B signaling pathway (Ikbkb). DNA binding 
activities of AP-1 and NFκB were diminished in activated 
Gli2A T-cells, whereas Gli2R T-cells showed enhanced 
binding of NFκB to DNA compared to WT T-cells [6]. 
Together our data show that Gli2-mediated transcription 
in T-cells modulates TCR signalling and T-cell activation. 
These observations link previous findings that 
Gli2A both alters T-cell repertoire selection [1, 3] and 
CD4+ Th differentiation [5], as modulation of both 
of these processes could be explained by ‘dampened’ 
TCR signaling. There are wide implications for these 
observations. Gli-activating Hh proteins may be 
upregulated in tissues during damage, repair or chronic 
inflammation. This raises the intriguing possibility 
that Hh and/or other Gli-activating ligands could act as 
novel immunomodulators when released by tissue. In 
evolutionary terms, a tissue-derived ligand that ‘down-
tunes’ TCR signals to favour Th2 differentiation would be 
useful if the tissue were infected with a parasite. It is also 
possible that Hh/Gli signaling between tissue and immune 
cells acts as a balance between acute inflammatory and 
immune resolution repair phases. Interestingly, several 
cancers, particularly of epithelial origin, express Hh 
ligands. The dampening of TCR signal transduction by 
Hh/Gli signaling to local T-cells could therefore be an 
unexplored mechanism of tumour immune evasion (Figure 
1). Hh pathway inhibitors are used therapeutically in some 
cancers, thus there may be additional hidden benefits to 
the use of these drugs in tumours that secrete Hh ligands. 
In summary, activation of Gli-dependent 
transcription in CD4+ T-cells acts to modulate TCR 
signals. The plastic nature of T-helper cells means that 
they are particularly susceptible to microenvironmental 
signals such as those potentially delivered by Gli-
activating ligands.  
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